308 related articles for article (PubMed ID: 18402508)
1. Parkinson's disease--Part 2: Treatment of motor symptoms.
Weintraub D; Comella CL; Horn S
Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
[TBL] [Abstract][Full Text] [Related]
2. The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms.
Snyder CH; Adler CH
J Am Acad Nurse Pract; 2007 Apr; 19(4):179-97. PubMed ID: 17430539
[TBL] [Abstract][Full Text] [Related]
3. The impact and management of nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease--Part 3: Neuropsychiatric symptoms.
Weintraub D; Comella CL; Horn S
Am J Manag Care; 2008 Mar; 14(2 Suppl):S59-69. PubMed ID: 18402509
[TBL] [Abstract][Full Text] [Related]
5. Levodopa-related motor complications--phenomenology.
Fox SH; Lang AE
Mov Disord; 2008; 23 Suppl 3():S509-14. PubMed ID: 18781677
[TBL] [Abstract][Full Text] [Related]
6. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.
Weintraub D; Comella CL; Horn S
Am J Manag Care; 2008 Mar; 14(2 Suppl):S40-8. PubMed ID: 18402507
[TBL] [Abstract][Full Text] [Related]
7. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
8. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced Parkinson's disease.
Diamond A; Jankovic J
Expert Rev Neurother; 2006 Aug; 6(8):1181-97. PubMed ID: 16893346
[TBL] [Abstract][Full Text] [Related]
11. Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care.
Chen JJ
Am J Manag Care; 2011 Oct; 17 Suppl 12():S322-7. PubMed ID: 22087553
[TBL] [Abstract][Full Text] [Related]
12. Limitations of current Parkinson's disease therapy.
Rascol O; Payoux P; Ory F; Ferreira JJ; Brefel-Courbon C; Montastruc JL
Ann Neurol; 2003; 53 Suppl 3():S3-12; discussion S12-5. PubMed ID: 12666094
[TBL] [Abstract][Full Text] [Related]
13. The nonmotor symptoms of Parkinson's disease--an overview.
Lim SY; Lang AE
Mov Disord; 2010; 25 Suppl 1():S123-30. PubMed ID: 20187234
[TBL] [Abstract][Full Text] [Related]
14. Problems with current pharmacologic treatment of Parkinson's disease.
Hurtig HI
Exp Neurol; 1997 Mar; 144(1):10-6. PubMed ID: 9126144
[TBL] [Abstract][Full Text] [Related]
15. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease.
Deogaonkar M; Subramanian T
Brain Res Brain Res Rev; 2005 Dec; 50(1):156-68. PubMed ID: 16026845
[TBL] [Abstract][Full Text] [Related]
17. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
18. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Encarnacion EV; Hauser RA
Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
[TBL] [Abstract][Full Text] [Related]
20. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
